DEVOTISSE Trademark

Trademark Overview


On Tuesday, February 14, 2017, a trademark application was filed for DEVOTISSE with the United States Patent and Trademark Office. The USPTO has given the DEVOTISSE trademark a serial number of 87335704. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Thursday, January 17, 2019. This trademark is owned by Allergan Sales, LLC. The DEVOTISSE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin; Pharmaceutical preparations used in connection with and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of pre...
devotisse

General Information


Serial Number87335704
Word MarkDEVOTISSE
Filing DateTuesday, February 14, 2017
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateThursday, January 17, 2019
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin; Pharmaceutical preparations used in connection with and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body
Translation of Words in MarkThe word DEVOTISSE has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 21, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Sales, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressIrvine, CA 92612

Trademark Events


Event DateEvent Description
Thursday, January 17, 2019ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Thursday, January 17, 2019ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Thursday, June 21, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, June 21, 2018NON-FINAL ACTION E-MAILED
Thursday, June 21, 2018NON-FINAL ACTION WRITTEN
Thursday, May 31, 2018LIE CHECKED SUSP - TO ATTY FOR ACTION
Thursday, May 31, 2018ASSIGNED TO LIE
Monday, November 13, 2017REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Friday, May 12, 2017NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, May 12, 2017LETTER OF SUSPENSION E-MAILED
Friday, May 12, 2017SUSPENSION LETTER WRITTEN
Friday, May 12, 2017EXAMINER'S AMENDMENT ENTERED
Friday, May 12, 2017NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, May 12, 2017EXAMINERS AMENDMENT E-MAILED
Friday, May 12, 2017EXAMINERS AMENDMENT -WRITTEN
Tuesday, May 9, 2017ASSIGNED TO EXAMINER
Tuesday, February 21, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, February 17, 2017NEW APPLICATION ENTERED IN TRAM